DK3377484T3 - Fremgangsmåder til behandling af multipel sklerose under anvendelse af pyrimidin- og pyridinforbindelser med btk- inhiberende aktivitet - Google Patents
Fremgangsmåder til behandling af multipel sklerose under anvendelse af pyrimidin- og pyridinforbindelser med btk- inhiberende aktivitet Download PDFInfo
- Publication number
- DK3377484T3 DK3377484T3 DK16805251.2T DK16805251T DK3377484T3 DK 3377484 T3 DK3377484 T3 DK 3377484T3 DK 16805251 T DK16805251 T DK 16805251T DK 3377484 T3 DK3377484 T3 DK 3377484T3
- Authority
- DK
- Denmark
- Prior art keywords
- btk
- pyrimidine
- treatment
- methods
- multiple sclerosis
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562256199P | 2015-11-17 | 2015-11-17 | |
| PCT/US2016/062154 WO2017087445A1 (en) | 2015-11-17 | 2016-11-16 | Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3377484T3 true DK3377484T3 (da) | 2023-11-27 |
Family
ID=57460611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16805251.2T DK3377484T3 (da) | 2015-11-17 | 2016-11-16 | Fremgangsmåder til behandling af multipel sklerose under anvendelse af pyrimidin- og pyridinforbindelser med btk- inhiberende aktivitet |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10716788B2 (enExample) |
| EP (2) | EP3377484B1 (enExample) |
| JP (1) | JP6891173B2 (enExample) |
| KR (1) | KR102780243B1 (enExample) |
| CN (1) | CN108884076B (enExample) |
| AU (1) | AU2016357735B2 (enExample) |
| BR (1) | BR112018007517B1 (enExample) |
| CL (1) | CL2018001252A1 (enExample) |
| DK (1) | DK3377484T3 (enExample) |
| ES (1) | ES2964946T3 (enExample) |
| FI (1) | FI3377484T3 (enExample) |
| HR (1) | HRP20231547T1 (enExample) |
| HU (1) | HUE064244T2 (enExample) |
| IL (1) | IL258978B (enExample) |
| LT (1) | LT3377484T (enExample) |
| MX (1) | MX386146B (enExample) |
| MY (1) | MY199473A (enExample) |
| NZ (1) | NZ741294A (enExample) |
| PH (1) | PH12018500736A1 (enExample) |
| PL (1) | PL3377484T3 (enExample) |
| PT (1) | PT3377484T (enExample) |
| RS (1) | RS64908B1 (enExample) |
| SI (1) | SI3377484T1 (enExample) |
| UA (1) | UA123159C2 (enExample) |
| WO (1) | WO2017087445A1 (enExample) |
| ZA (1) | ZA201802348B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3001735A1 (en) * | 2015-11-04 | 2017-05-11 | Merck Patent Gmbh | Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity |
| CN108884076B (zh) * | 2015-11-17 | 2021-07-30 | 默克专利有限公司 | 使用具有btk抑制活性的嘧啶和吡啶化合物治疗多发性硬化症的方法 |
| KR20210022674A (ko) * | 2018-06-19 | 2021-03-03 | 메르크 파텐트 게엠베하 | 1-(4-｛[6-아미노-5-(4-페녹시-페닐)-피리미딘-4-일아미노]-메틸｝-4-플루오로-피페리딘-1-일)-프로펜온의 신규한 결정 형태, 이의 염 형태, 및 이를 수득하는 방법 |
| HRP20241737T1 (hr) * | 2018-07-20 | 2025-02-28 | Merck Patent Gmbh | Supstituirani amino-pirimidinski spoj za upotrebu u postupku za liječenje i prevenciju multiple skleroze |
| IL294560A (en) | 2020-01-20 | 2022-09-01 | Genzyme Corp | Medicinal tyrosine kinase inhibitors for relapsing multiple sclerosis |
| CN112250666B (zh) * | 2020-10-09 | 2022-01-14 | 广东东阳光药业有限公司 | 取代的嘧啶类化合物及其用途 |
| CA3200332A1 (en) * | 2020-12-02 | 2022-06-09 | Telios Pharma, Inc. | Methods and compositions for treating an ophthalmic condition |
| WO2022121670A1 (zh) | 2020-12-10 | 2022-06-16 | 苏州科睿思制药有限公司 | Tolebrutinib的晶型及其制备方法和用途 |
| US11866421B2 (en) | 2021-05-31 | 2024-01-09 | Epigen Biosciences, Inc. | Pyrimidine and pyridine amine compounds and usage thereof in disease treatment |
| CN119744171A (zh) | 2022-06-24 | 2025-04-01 | 默克专利股份公司 | 自身免疫病和炎性疾病的治疗方案 |
| WO2024099241A1 (zh) * | 2022-11-07 | 2024-05-16 | 天津征程医药科技有限公司 | 氘代的嘧啶衍生物以及包含该化合物的药物组合物 |
| WO2025096900A1 (en) * | 2023-11-03 | 2025-05-08 | Board Of Regents, The University Of Texas System | Synthetic network materials and methods of making and use thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998024782A2 (en) * | 1996-12-05 | 1998-06-11 | Amgen Inc. | Substituted pyrimidine compounds and their use |
| CN101676285A (zh) | 2004-03-30 | 2010-03-24 | 沃泰克斯药物股份有限公司 | 用作jak和其它蛋白激酶抑制剂的氮杂吲哚 |
| GB0512844D0 (en) * | 2005-06-23 | 2005-08-03 | Novartis Ag | Organic compounds |
| ES2673973T3 (es) * | 2006-09-22 | 2018-06-26 | Pharmacyclics Llc | Inhibidores de tirosina cinasa de Bruton |
| US20100311736A1 (en) * | 2007-10-22 | 2010-12-09 | Glaxosmithkline Llc | Pyridosulfonamide derivatives as p13 kinase inhibitors |
| WO2011029804A1 (en) | 2009-09-10 | 2011-03-17 | F. Hoffmann-La Roche Ag | Inhibitors of jak |
| KR101301533B1 (ko) | 2010-02-09 | 2013-09-04 | 한미사이언스 주식회사 | 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체 |
| PT2718270T (pt) | 2011-06-10 | 2022-07-29 | Merck Patent Gmbh | Composições e métodos para a produção de compostos de pirimidina e piridina com atividade inibidora de btk |
| TW201414734A (zh) * | 2012-07-10 | 2014-04-16 | Takeda Pharmaceutical | 氮雜吲哚衍生物 |
| GEP201606597B (en) * | 2012-11-02 | 2017-01-10 | Pfizer | Bruton's tyrosine kinase inhibitors |
| WO2014093230A2 (en) * | 2012-12-10 | 2014-06-19 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
| US9598398B2 (en) * | 2013-04-04 | 2017-03-21 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| BR112015032330B1 (pt) * | 2013-06-26 | 2019-01-22 | Abbvie Inc. | carboxamidas primárias como inibidores de bkt |
| SG11201600159TA (en) * | 2013-07-31 | 2016-02-26 | Merck Patent Gmbh | Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof |
| KR20160058889A (ko) | 2013-09-22 | 2016-05-25 | 칼리토르 사이언시즈, 엘엘씨 | 치환된 아미노피리미딘 화합물 및 이용 방법 |
| CA3001735A1 (en) * | 2015-11-04 | 2017-05-11 | Merck Patent Gmbh | Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity |
| CN108884076B (zh) * | 2015-11-17 | 2021-07-30 | 默克专利有限公司 | 使用具有btk抑制活性的嘧啶和吡啶化合物治疗多发性硬化症的方法 |
-
2016
- 2016-11-16 CN CN201680078780.9A patent/CN108884076B/zh active Active
- 2016-11-16 AU AU2016357735A patent/AU2016357735B2/en active Active
- 2016-11-16 HR HRP20231547TT patent/HRP20231547T1/hr unknown
- 2016-11-16 DK DK16805251.2T patent/DK3377484T3/da active
- 2016-11-16 BR BR112018007517-5A patent/BR112018007517B1/pt active IP Right Grant
- 2016-11-16 FI FIEP16805251.2T patent/FI3377484T3/fi active
- 2016-11-16 EP EP16805251.2A patent/EP3377484B1/en active Active
- 2016-11-16 MY MYPI2018701467A patent/MY199473A/en unknown
- 2016-11-16 KR KR1020187014258A patent/KR102780243B1/ko active Active
- 2016-11-16 PT PT168052512T patent/PT3377484T/pt unknown
- 2016-11-16 ES ES16805251T patent/ES2964946T3/es active Active
- 2016-11-16 RS RS20231155A patent/RS64908B1/sr unknown
- 2016-11-16 SI SI201631768T patent/SI3377484T1/sl unknown
- 2016-11-16 PL PL16805251.2T patent/PL3377484T3/pl unknown
- 2016-11-16 WO PCT/US2016/062154 patent/WO2017087445A1/en not_active Ceased
- 2016-11-16 MX MX2018005463A patent/MX386146B/es unknown
- 2016-11-16 JP JP2018525702A patent/JP6891173B2/ja active Active
- 2016-11-16 UA UAA201806687A patent/UA123159C2/uk unknown
- 2016-11-16 NZ NZ741294A patent/NZ741294A/en unknown
- 2016-11-16 LT LTEPPCT/US2016/062154T patent/LT3377484T/lt unknown
- 2016-11-16 US US15/352,657 patent/US10716788B2/en active Active
- 2016-11-16 EP EP23195454.6A patent/EP4295910A3/en active Pending
- 2016-11-16 HU HUE16805251A patent/HUE064244T2/hu unknown
-
2018
- 2018-04-03 PH PH12018500736A patent/PH12018500736A1/en unknown
- 2018-04-10 ZA ZA2018/02348A patent/ZA201802348B/en unknown
- 2018-04-26 IL IL258978A patent/IL258978B/en active IP Right Grant
- 2018-05-09 CL CL2018001252A patent/CL2018001252A1/es unknown
-
2020
- 2020-06-08 US US16/946,145 patent/US20200316068A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3377484T3 (da) | Fremgangsmåder til behandling af multipel sklerose under anvendelse af pyrimidin- og pyridinforbindelser med btk- inhiberende aktivitet | |
| DK3356350T3 (da) | Isoindolinonhæmmere af mdm2-p53-interaktionen med anticanceraktivitet | |
| DK3253865T3 (da) | Fremgangsmåder til forbedring af virkningen af terapeutiske immunceller | |
| IL253986A0 (en) | Systems and methods for improving heart-rate variability | |
| DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
| KR20180084817A (ko) | 항-siglec-9 항체 및 이의 이용 방법 | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| DK3521282T3 (da) | Quinazolinderivater anvendt til behandling af hiv | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3307262T3 (da) | Forbindelser til anvendelse ved behandling af neuromuskulære lidelser | |
| DK3139925T3 (da) | Valbenazin-doseringssystem til behandling af hyperkinetiske bevægelsesforstyrrelser | |
| DK3504187T3 (da) | Anvendelse af pridopidin til behandling af funktionel tilbagegang | |
| DK3303339T3 (da) | Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| EP3357922A4 (en) | PYRIMIDINE OR PYRIDOPYRIDONE COMPOUND AND USE THEREOF | |
| DK3253412T3 (da) | Anti-cd40l-antistoffer og fremgangsmåder til behandling af cd40l-forbundne sygdomme eller forstyrrelser | |
| DK3157534T3 (da) | Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande | |
| DK3292145T3 (da) | Fc-mutanter med modificeret funktionel aktivitet | |
| DK3331879T3 (da) | Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne | |
| SG10202005292UA (en) | Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity | |
| DK3099298T3 (da) | Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner | |
| DK3710000T3 (da) | Tradipitant til anvendelse til behandling af gastroparese | |
| DK3391902T5 (da) | Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati | |
| DK3606929T3 (da) | Beta-nicotinat-ester-nukleotider og fremgangsmåder til fremstilling af samme |